Remove Headlines Biopharma-Culture
article thumbnail

Achieving Targeted Delivery with Nanoscale Systems

PharmaTech

link] org/10.1016/j.jddst.2023.104724

Dosage 52
article thumbnail

FDA to ask Sarepta to stop shipping Duchenne gene therapy

BioPharma Dive

Skip to main content CONTINUE TO SITE ➞ Dont miss tomorrows biopharma industry news Let BioPharma Dives free newsletter keep you informed, straight from your inbox. By BioPharma Dive staff • Updated June 30, 2025 Yujin Kim / MedTech Dive, original photo courtesy of U.S. Sign up A valid email address is required.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Resolving challenges with product recovery in biopharma manufacturing

Pharmaceutical Technology

Breakthroughs in therapies containing monoclonal antibodies (mAbs) are showing ever-greater potential in treating a range of diseases, alongside biopharma manufacturers facing the challenge of keeping up with demand for production while controlling costs. This can result in reductions in costs for our customers.”

article thumbnail

How to get acquisition ready – a seller’s guide to merger and acquisition in pharma

pharmaphorum

In pharma, multi-billion-dollar deals dominate M&A headlines, but most deals are far shorter of this range and generally lie between $10-$500 million. In 2018, over 60% of all new molecular entities came from smaller biopharma firms, compared with just over 30% in 2009. Post-acquisition compliance.

article thumbnail

Advancements in Biopharma Spur Innovation

PharmaTech

The global biopharma industry is expected to increase at a compound annual growth rate of 8.97% from 2025 to 2030; this growth is suspected to result from a demand for targeted therapies, new alliances, and increased innovation (1). Next-Generation Biotherapeutics eBook 2025 April.

Dosage 52
article thumbnail

Panel urges FDA to remove warnings on hormonal menopause therapy

BioPharma Dive

Skip to main content CONTINUE TO SITE ➞ Dont miss tomorrows biopharma industry news Let BioPharma Dives free newsletter keep you informed, straight from your inbox. Some medical associations broadly recommend MHT, but caution that there are potential risks and emphasize conversations with physicians. inhibitors. inhibitors.

article thumbnail

FDA’s AI tool ‘Elsa’ is here, and the industry has questions

BioPharma Dive

Skip to main content CONTINUE TO SITE ➞ Dont miss tomorrows biopharma industry news Let BioPharma Dives free newsletter keep you informed, straight from your inbox. By Delilah Alvarado • May 13, 2025 Keep up with the story. You can unsubscribe at anytime. Sign up A valid email address is required. Please select at least one newsletter.